

Effects of DMSO on Diminazene Efficacy in Experimental Murine *T. brucei* Infection

¹K.I. Eghianruwa and ²S.M. Anika

¹Department of Veterinary Physiology, Biochemistry and Pharmacology,
University of Ibadan, Nigeria

²Department of Veterinary Physiology and Pharmacology, University of Nigeria, Nsukka, Nigeria

Abstract: This study evaluated the influence of dimethyl sulfoxide (DMSO) daily supplementation on diminazene treatment of trypanosomosis. Four groups of *Trypanosoma brucei brucei* infected rats received 7.0 mg/kg diminazene aceturate on day 7 post infection. Three of the four groups received different doses of DMSO (0.5, 1.0 and 2.0 g/kg, respectively) in addition to diminazene treatment. The changes in hematological parameters and the weights of liver, spleen and heart caused by *T. brucei* infection were monitored and used to assess the efficacy of treatment. The prepatent period of infection was four days. Infection caused significant increases in WBC count, spleen and liver weights but it caused decreases in PCV, HB and RBC by day 7 post infection (PI₇). By PI₁₄, spleen weight and WBC counts were reduced from the PI₇ level without treatment. Diminazene/DMSO combination did not reduce liver weight or increased hematological parameters more significantly than diminazene treatment alone. Increase in the dose of DMSO caused increases in liver weight. Diminazene/DMSO combination reduced spleen weight more significantly than diminazene treatment alone. Diminazene/DMSO combination delayed re-emergence of parasites beyond PT₂₁ at which time parasites were detected in the blood of rats treated only with diminazene. The limited advantages of diminazene/DMSO combination over diminazene alone as well as the possible liver toxicity of DMSO at high doses would not make DMSO supplementation a viable addition to trypanosomosis chemotherapy.

Key words: Diminazene, DMSO, liver weight, parasitemia, rat, spleen weight, trypanosome

INTRODUCTION

Despite many decades of research and actions at vector and chemotherapeutic control of trypanosomosis, effective control strategies have yet to materialize. The two traditional methods of using chemotherapeutic drugs for treatment and prophylaxis as well as insecticides for vector control have met with unsatisfactory outcomes. Drug resistance and toxicity are two important complicating factors in the chemotherapy of trypanosomosis and the widespread use of insecticides is not environmentally friendly. The failure of these traditional methods has been complicated by the lack of vaccine and new drugs. New drug development for the control of trypanosomosis is unappealing for commercial reasons (Trouiller and Olliaro, 1999; Murray *et al.*, 2000) hence; it is pertinent to find how the old drugs can do their therapeutic best.

Dimethyl Sulfoxide (DMSO) has antioxidant properties being a free radical scavenger with high degree of specificity for the damaging hydroxyl radical (Panganamala *et al.*, 1976; Santos *et al.*, 2003). The

cardiovascular protective effect of DMSO in copper-deficient rats is thought to occur by an antioxidant mechanism (Yokoi *et al.*, 1990). With the allusion that oxidant/antioxidant imbalance contributes to the pathogenesis of trypanosomosis, ascorbic acid, an antioxidant has been combined with diminazene in the treatment of *T. brucei* infection. Treatment with diminazene/ascorbic acid combination led to better remission of the disease than diminazene alone (Eghianruwa *et al.*, 2009). The result with ascorbic acid indicated that trypanocide/antioxidant combination may enhance efficacy of trypanocides. Hence, this study was undertaken to elucidate the influence of DMSO (a compound with antioxidant properties) on diminazene efficacy in experimental *T. brucei* infection.

MATERIALS AND METHODS

Eighty Wistar albino rats (90-110 g) of mixed sexes procured from the Nigerian Institute for Trypanosomiasis Research, Vom, Nigeria were housed in standard rat cages in a fly proof house. The animals were humanely cared

for in compliance with the principles stipulated in the Guide for the Care and Use of Laboratory Animals (National Academy of Sciences, 2010). The study was conducted at the University of Ibadan, Nigeria in 2010 and the institution's ethics committee approved and monitored the protocol. Animals were fed ad libitum with commercially formulated 8 mm pelletized mouse cubes (Ladokun Feeds, Ibadan, Nigeria). Water was provided *ad libitum* using plastic bottles equipped with sipper tubes. Excess feed and water were removed and replaced with fresh ones daily.

Animals were divided into six groups (I-VI) and allowed to acclimatize for 2 weeks before commencement of experiments. Group I (n = 5) served as uninfected control. Groups II to VI which consisted of 15 rats each were infected with the Federe strain of *T. brucei brucei* obtained from the Nigerian Institute for Trypanosomosis Research (NITR), Vom, Nigeria where it was preserved in liquid nitrogen. The parasites were maintained in rats by serial passage after removal from liquid nitrogen. Infection of experimental animals was by intraperitoneal injection of 1×10^6 trypanosome cells obtained from the tail blood of a rat showing heavy parasitemia. The blood was diluted in normal saline to obtain trypanosome concentration of 1×10^5 per mL. Each animal received 0.1 mL of the diluted blood.

Seven days post infection (PI₇), the infected rats in groups III, IV, V, and VI were treated once with 7.0 mg/kg diminazenediacetate (Trypadim®, Merial, France) injected intramuscularly. The rats in group II were untreated (infected control). Beginning from the day of diminazene treatment (PI₇; DOT), rats in groups IV, V and VI received daily oral supplement of dimethyl sulfoxide (DMSO) (BDH Laboratory Reagents, England) at 0.5, 1.0 and 2.0 g/kg, respectively in addition to the single diminazene treatment. The DMSO required by each group per day was dispensed in small volumes of water. Fresh water was given after medicated water was exhausted.

Five rats in group II were sacrificed on PI₇ to generate data for the day of diminazene treatment (DOT). The three surviving rats in the group were sacrificed on PI₁₄. Five rats were sacrificed from each of groups III-VI on days 7, 14 and 21 post diminazene treatment. The sacrificed animals were euthanized with chloroform (BDH Laboratory Reagents, England) inhalation. Following euthanasia, blood was withdrawn from the hearts into sample bottles containing Na₂EDTA. The liver, heart and spleen were dissected out and immediately weighed. The organs were then processed routinely for histopathology and sections stained with hematoxylin and eosins were examined with the light microscope.

Changes in parasitemia; Packed Cell Volume (PCV); Haemoglobinemia (Hb); Erythrocyte (RBC) count; leukocyte (WBC) count; weights of the liver, spleen and

heart were measured to determine the effect of DMSO supplementation on diminazene efficacy. The PCV, Hb and RBC, WBC were determined using established methods as described by (Walters *et al.*, 1986). The rapid matching method described by (Herbert and Lumsden, 1976) was used to estimate parasitaemia in blood samples.

ANALYSIS OF RESULTS

The differences in the means of parameters were analyzed statistically with InStat® software (GraphPad Inc., USA) using one-way analysis of variance (ANOVA) (for ≥ 3 means) and two-tailed p-value (for 2 means). Probability values less or equal to 0.05 ($p \leq 0.05$) were considered significant.

Infection effects: Parasites appeared in the blood of infected rats from PI₄. The first deaths were recorded on PI₉. By PI₁₄, only three of the fifteen infected animals in group II (infected control) survived; five were sacrificed on PI₇; while seven died between PI₉ and PI₁₂. *Trypanosoma brucei brucei* caused significant ($p < 0.05$) increases in liver and spleen weights by PI₇. There were no significant ($p > 0.05$) increases in heart weight. Pack cell volume, haemoglobin content and RBC counts were significantly ($p < 0.05$) reduced by the infection by PI₇. The significant ($p < 0.05$) increase in WBC count on PI₇ was significantly reversed by PI₁₄ (Fig. 1).

By PI₁₄, liver weight, PCV, Hb and RBC in group II had increased by 8.15, 6.35, 3.93, and 13.68%, respectively from their values on PI₇ (Table 1). On the contrary, on PI₁₄, spleen weight and WBC count were respectively 21.81 and 47.20% less than the values recorded on PI₇. The changes in WBC count between PI₇ and PI₁₄ were significant ($p < 0.05$). The histopathological lesions observed on PT₂₁ include moderate hyperplasia of Kupffer cells with haemosiderin pigments, diffused vacuolation of hepatocytes and moderate lymphocytic and mild neutrophilic infiltrates in the portal triad of the liver (Fig. 2). Germinal center hyperplasia, proliferation of the




Fig. 1: Effects of DMSO supplementation on WBC count in *T. brucei* infected and diminazene treated rats

Table 1: Effect of *T. b. brucei* infection on organ weights and haematology in infected and untreated rats. Values are expressed as Means±S.D. Values in a row with different superscripts differ significantly (p<0.05)

Parameter	Uninfected (n = 5)	Infected; untreated	
		PI ₇ (n = 5)	PI ₁₄ (n = 3)
Liver weight (% BW)	3.58±0.33*	5.07±0.35*	5.52±0.75*
Spleen weight (% BW)	0.36±0.08*	2.98±0.61*	2.33±0.46*
Heart weight (%BW)	0.35±0.06*	0.31±0.06*	0.37±0.06*
PCV (%)	37.5±2.63*	25.75±4.1*	27.5±2.12*
Hb (g/dL)	11.8±0.73*	8.55±1.21*	8.9±0.57*
RBCx10 ⁹ /mm ³	7.07 ± 0.53*	4.48±0.47*	5.19±0.03*
WBC/mm ³	10,025.00±2,080.11*	16,100.00±4,177.72*	8,500.00±707.11 [§]




Fig. 2: Photomicrograph of rat liver showing periportal cellular infiltration on day 21 following infection with *T. b. brucei* (H&E) × 25




Fig. 3: Photomicrograph of rat spleen showing haemosiderosis (arrow) on day 21 following infection with *T. b. brucei*. (H&E) × 25

reticular tissue, macrophages and plasma cells and marked deposits of haemosiderin pigments were observed in the spleen (Fig. 3). No histopathological lesions were seen in the heart.

Treatment effects on liver weight and histopathology:

Treatment with diminazene alone and in combination with DMSO resulted in marginal, insignificant (p>0.05) reduction in liver weight from the DOT value of 5.07±0.35% BW by PT₇ (Fig. 4). The variations in the means of liver weight between the treated groups on




Fig. 4: Effects of DMSO daily supplementation on liver weight in *T. b. brucei* infected and diminazene treated rats

PT₇ were also not significant (p>0.05). There were no significant differences (p>0.05) in the mean values of liver weight on PT₁₄ and PT₂₁ in both the diminazene alone and diminazene/DMSO groups. The mean liver weight values of 4.57±0.41 and 4.33±0.55% BW on PT₂₁ in the diminazene and diminazene/0.5 g/kg DMSO groups respectively were significantly (p<0.05) lower than the value on DOT. Increase in the dose of DMSO from 0.5 to 1.0 and 2.0 g/kg gave generally higher mean liver weights. The mean liver weight values of 6.08±0.20 and 5.67±0.35% BW on PT₁₄ and PT₂₁, respectively in the 2.0 g/kg DMSO supplemented group was significantly (p<0.05) higher than the values recorded in the diminazene, diminazene/0.5g/kg DMSO groups and on DOT. Histopathological lesions were observed by PT₂₁ in both the diminazene and diminazene/DMSO groups.

Diminazene/DMSO effects on spleen weight and histopathology:

The prominent increase in spleen size and weight caused by the infection with *T. brucei* was significantly (p<0.05) reduced from the DOT value on PT₇ by diminazene and diminazene/DMSO combinations without any significant (p>0.05) differences in the reduction caused by the two treatment options (Fig. 5).

The combinations of diminazene with 1.0 and 2.0 g/kg DMSO caused marginally lower but statistically

Table 2: Effects of diminazene alone and diminazene/DMSO combinations on hematological parameters in *T. b. brucei* infected rats. Values are expressed as Means±S.D. PI = post infection; PT = post treatment while superscript indicate the day; Values in a column with different superscript differ significantly (p<0.05)

Treatment group	Test day	Parameter		
		PCV (%)	Hb (g/dL)	RBC (x10 ⁶ /mm ³)
Uninfected		39.75±2.22 *	13.45±0.76 *	6.87±0.48 *
DOT (PI ₇)	PI ₇	25.75±4.10 [♣]	8.55±1.21 [♣]	4.48±0.47 [♣]
Diminazene (7 mg/kg)	PT ₇	39.50±3.42 *	12.18±1.21*	6.96±0.75*
	PT ₁₄	41.75±4.19 *	13.45±1.43*	7.36±0.54*
	PT ₂₁	47.25±0.96 [§]	15.18±0.56 [§]	7.92±0.38 [§]
Diminazene + 0.5 g/kg DMSO	PT ₇	37.00±2.16 *	12.65±0.53*	6.35±0.52*
	PT ₁₄	45.00±2.45 [§]	14.7±0.68 [§]	7.88±0.44 [§]
	PT ₂₁	45.00±2.45 [§]	14.7±0.68 [§]	7.88±0.44 [§]
Diminazene + 1.0 g/kg DMSO	PT ₇	38.75±2.99 *	12.95±1.02*	6.75±0.46*
	PT ₁₄	41.25±3.95 *	13.22±1.18*	7.70±0.50 [§]
	PT ₂₁	46.25±4.27 [§]	15.00±1.42 [§]	7.84±0.71 [§]
Diminazene + 2.0 g/kg DMSO	PT ₇	34.75±2.99 [♠]	11.73±1.11 [♠]	6.16±0.40*
	PT ₁₄	42.33±4.04 [™]	13.33±1.68*	7.16±0.39*
	PT ₂₁	44.50±1.50 [§]	15.05±0.35 [§]	7.47±0.16 [§]




Fig. 5: Effects of DMSO daily supplementation on spleen weight in *T. b. brucei* infected and diminazene treated rats




Fig. 6: Effects of DMSO daily supplementation on parasitemia in *T. b. brucei* infected and diminazene treated rats

insignificant (p>0.05) reduction in spleen weight compared to that of diminazene treatment alone. The mean values of spleen weight on PT₇ in all treated groups were significantly (p<0.01) higher than the values

obtained on PT₁₄. However, there were no significant (p>0.05) differences in the mean values of spleen weight between the groups treated with diminazene alone and those with diminazene/DMSO combinations. On PT₂₁, diminazene plus 2.0 g/kg DMSO produced significant (p<0.05) reduction of mean spleen weight from PT₁₄ value. The mean spleen weight of 0.52±0.01% BW in the diminazene/2.0 g/kg DMSO group on PT₂₁ was the lowest recorded and the value was significantly (p<0.05) lower than that recorded in the group which received diminazene treatment alone.

Diminazene/DMSO effects on hematology and parasitemia:

Treatment of *T. b. brucei* infection with diminazene and diminazene/DMSO combinations significantly (p<0.01) reversed the depressed PCV, Hb and RBC by PT₇. There were no significant (p>0.05) differences in the mean values of PCV, Hb and RBC in both the diminazene and diminazene/DMSO groups on 7 PT₇. These hematological parameters fully returned to normal by PT₇ in all treated groups as there was no significant (p>0.05) difference between the values in the treated groups and uninfected rats (Table 2). The parameters also rose steadily from PT₇ to PT₂₁. The PCV and Hb concentration in all treatment groups on PT₂₁ were significantly (p<0.001) higher than the values recorded in normal rats.

The increase in mean WBC count was reversed within seven days in untreated rats. Treatment with diminazene with and without DMSO also caused significant reduction in WBC count by PT₇. The mean WBC count was significantly (p<0.05) lower in the group treated with diminazene alone than in the diminazene/DMSO groups. There were no statistical differences in the mean WBC count in all treated groups by PT₁₄ and PT₂₁ (Fig. 1).

Diminazene alone and in combinations with DMSO were effective in clearing parasites from the blood by PT₇.

Infection relapsed only in the diminazene treated group by PT₂₁ (Fig. 6).

DISCUSSION

The reduced PCV, Hb and RBC levels which are indicative of anemia have been reported consistently by other workers (Losos and Ikede, 1972; Murray, 1979; Jenkins and Facer, 1985; Bengaly *et al.*, 2002; Kaikabo and Salako, 2006; Toma *et al.*, 2008; Eghianruwa *et al.*, 2009). The observed increases in the weights of liver and spleen are in agreement with those of Morrison *et al.* (2005) and Kaikabo and Salako (2006). The histopathological lesions observed in this study have also been described earlier (Eghianruwa *et al.*, 2009). The absence of lesion in the heart which is reported here is contrary to the observation of (Kaikabo and Salako, 2006) but consistent with earlier report (Eghianruwa *et al.*, 2009). The infection with *T. brucei* in this study produced leukocytosis followed within seven days by leucopenia. This pattern of response of WBC has been reported in *T. evansi* infection in dogs in which leukocytosis was detected on day 6 and leucopenia on day 12 post infection (De La Rue *et al.*, 2000). Toma *et al.* (2008) reported leucocytosis in *T. congolense* infected rabbits. Leucopenia has been reported by several authors (Losos and Ikede, 1972; Anosa, 1988). The discrepancies in these reports may be attributed, in part, to the time of observation. Early response to trypanosome infection has been shown to involve cellular proliferation especially of lymphocytes (De La Rue *et al.*, 2000). The level to which this response proceeds is thought to be due to the level of tolerance. It has been postulated that tolerant animals develop leukocytosis and non-tolerant ones develop leucopenia (Paling *et al.*, 1991).

Diminazene alone or in combination with DMSO supplementation was ineffective in reducing liver weight but both treatment protocols caused consistent reduction in spleen weight. Treatment with diminazene plus daily supplementation with 2 g/kg DMSO was more effective on the long run in reducing spleen weight since the mean spleen weight on day 21 PT was significantly lower than the corresponding value in the group treated with diminazene alone. This result is contradictory to that obtained with the liver in which increase in the dose of DMSO exacerbated the increased liver weight caused by the infection. There is no data in the literature on the combination of DMSO and a trypanocide but this observation have been made in *T. congolense* infection and its cause attributed, at least in part, to hepatotoxicity by DMSO (Eghianruwa and Anika, unpublished data). This observation has also been made when diminazene was combined with high doses of ascorbic acid in *T. brucei* infection (Eghianruwa *et al.*, 2009). Apart from hepatotoxicity induced by high doses of DMSO, these

observations may be due to the fact that certain antioxidants become prooxidants at high doses. This condition has been documented in the case of vitamins E and C (Kontush *et al.*, 1996; Kraus *et al.*, 2004; Eze and Ochike, 2007).

Diminazene alone or in combination with DMSO was ineffective in healing the histopathological lesions observed in the liver and spleen. These results are contradictory to those obtained with ascorbic acid in which diminazene treatment followed by supplementation with 200 mg/kg ascorbic acid was effective in healing the hepatic and splenic histopathological lesions (Eghianruwa *et al.*, 2009).

Treatments with diminazene alone and in combination with DMSO were equally effective in completely reversing the depressed PCV, Hb and RBC levels due to the infection. Drug treatment did not appear to have significant effect on WBC count since the leukocytosis recorded on PI₇ spontaneously reverted to leucopenia by PI₁₄ without drug treatment. The levels of WBC in the untreated group by PI₁₄ and in the treated groups by PT₇ (14 days after infection) were not significantly different.

Treatment with diminazene followed by DMSO supplementation appears to have superiority over treatment with diminazene alone in reducing spleen weight and delaying relapse. Both treatments were equally effective in restoring hematological values. The ineffectiveness in restoring the liver at low doses and possible hepatotoxicity at high doses makes diminazene/DMSO combination an unlikely candidate in the therapy of trypanosomiasis. This is further reinforced by the knowledge that DMSO in combination with diminazene had no outstanding effect over diminazene treatment alone in *T. congolense* infection (Eghianruwa and Obidike, 2011).

ACKNOWLEDGMENT

The authors acknowledge the technical support of Mrs. J. Ademakinwa and Mrs. A. F. Adeyemi, staff of Clinical Pathology Laboratory, Faculty of Veterinary Medicine, University of Ibadan. The technical contribution of staff of the histopathology laboratory, Faculty of Veterinary Medicine, University of Ibadan, Messrs J. U. Augustin, A. O Nwagbara and I. C. Mpama is highly appreciated.

REFERENCES

- Anosa, V.O., 1988. Hematological and biochemical changes in human and animal trypanosomiasis part I. Rev. Elev. Med. Vet. Pays. Trop., 41: 65-78.

- Bengaly, Z., I. Sidibe, H. Boly, L. Sawadogo and M. Desquesnes, 2002. Comparative pathogenicity of three genetically distinct *T. congolense* in inbred Balb/c mice. *Vet. Parasitol.*, 105: 111-118.
- De La Rue, M.L., R.A.M. Silva, J.H.S. Silva and G.A. De Carli, 2000. Leukocytes and Reticulocytes Counts in Acute Infection of Dogs with *Trypanosoma evansi* (Steel, 1885) Balbiani, 1888. *Rev. Latinoam. Microbiol.*, 42: 163-166.
- Eghianruwa, K.I., S.M. Anika and S.O. Akpavie, 2009. Efficacy of diminazene with and without ascorbic acid supplementation in *T. brucei* infected rats. *Trop. Vet.*, 27: 20-36.
- Eghianruwa, K.I. and R.I. Obidike, 2011. Comparative effects of antioxidants-ascorbic acid, DMSO, tocopherol and selenium-on organ masses and hematology following diminazene treatment of experimental murine *T. congolense* infection. *Ani. Prod. Res. Adv.*, 7: 134-140.
- Eze, J.I. and B.O. Ochiike, 2007. Effect of dietary vitamin E supplementation on Trypanosomabrucei infected mice. *Trop. Vet.*, 25: 18-25.
- Herbert, W.J. and W.H.R. Lumsden, 1976. Trypanosomabrucei, a rapid "matching" method for estimation of host's parasitemia. *Exp. Parasitol.*, 40: 427-431.
- Jenkins, G.C. and C.A. Facer, 1985. Hematology of African Trypanosomiasis. In: Tizard, I., (Ed.), *Immunology and Pathogenesis of Trypanosomiasis*. CRC Press, Boca Raton, pp: 13-44.
- Kaikabo, A.A. and M.A. Salako, 2006. Effects of vitamin E supplementation on anemia and tissue pathology in rats infected with *Trypanosomabrucei* (Federe strain). *Trop. Vet.*, 24: 46-51.
- Kontush, A., B. Finckh, B. Karten, A. Kohlschu and U. Beisiegel, 1996. Antioxidant and prooxidant activity of [alpha]-tocopherol in human plasma and low density lipoprotein. *J. Lipid Res.*, 37: 1436-1448.
- Kraus, V.B., J.L. Huebner, T. Stabler, C.M. Flahiff, L.A. Setton, C. Fink, V. Vilim and A.G. Clark, 2004. Ascorbic acid increases the severity of spontaneous knee osteoarthritis in a guinea pig model. *Arthritis Rheum.*, 50: 1822-1831.
- Losos, G.J. and B.O. Ikede, 1972. Review of pathology of diseases in domestic and laboratory animals caused by *Trypanosoma congolense*, *T. vivax*, *T. brucei*, *T. rhodesiense* and *T. gambiense*. *J. Vet. Pathol.*, 9: 1-17.
- Morrison, W.I., M. Murray and C.A. Hinson, 2005. The response of the murine lymphoid system to a chronic infection with *Trypanosoma congolense*. II. The lymph nodes, thymus and liver. *J. Pathol.*, 138: 273-288.
- Murray, M., 1979. Anemia of Bovine African Trypanosomiasis: An Overview In: Losos, G. and A. Choulnard, (Eds.), *Pathogenicity of Trypanosomes*. IDRC No. 32: 121-127.
- Murray, H.W., J. Pépin, T.B. Nutman, S.L. Hoffman and A.A.F. Mahmoud, 2000. Recent advances: Tropical medicine. *Br. Med. J.*, 320: 490-494.
- National Academy of Sciences, 2010. Guide for the Care and Use of Laboratory Animals. Retrieved from: <http://www.nap.edu/catalog/12910.html>, (Accessed on: June 21, 2010).
- Paling, W., S.K. Moloo, J.R. Scott, F.A. Mcodimba, L.L. Logan-Henfrey, M. Murray and D.J.L. Williams, 1991. Susceptibility of N'Dama and Boran cattle to tsé-tsé transmitted primary and rechange infections with a homologous serodeme of *Trypanosoma congolense*. *Parasitol. Immunol.*, 13: 413-425.
- Panganamala, R.V., H.M. Sharma and R.E. Heikkila, 1976. Role of hydroxyl radical scavengers, dimethyl sulfoxide, alcohols and methional in the inhibition of prostaglandin synthesis. *Prostaglandins*, 11: 599-607.
- Santos, N.C., J. Figueira-Coelho, J. Martins-Silva and C. Saldanha, 2003. Multidisciplinary utilization of dimethyl Sulfoxide, pharmacological, cellular and molecular aspects. *Biochem. Pharmacol.*, 65: 1035-1041.
- Toma, I., D.Y. Shinggu, W. Ezekiel and J.T. Barminas, 2008. Effect of intraperitoneal administration of vitamin c (ascorbic acid) on anemia in experimental *Trypanosoma congolense* infected rabbits. *Afr. J. Pure Appl. Chem.*, 2: 37-40.
- Trouiller, P.T. and P.L. Olliaro, 1999. Drug development output from 1975 to 1996: what proportion for tropical diseases? *Int. J. Infect. Dis.*, 3: 61-63.
- Walters, N.J., B.H. Estridge and A.P. Reynolds, 1986. *Basic Medical Laboratory Techniques*. Demar Publishers Inc., New York.
- Yokoi, K., M. Kimura and Y. Itokawa, 1990. Cardiovascular but not renal effects of copper deficiency are inhibited by dimethyl sulfoxide. *Nutr. Res.*, 10: 467-477.